ARCHIVES

Assembly of Scientists, started as a result of conflict of interest controversy, plans Sept. 14 meeting.

This article is from The Cancer Letter archive.

Vol. 31 No. 32 | September 9, 2005

Download PDF Visit The Full Archive

Related Articles

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

In Brief: Bishop No Longer Candidate For NCI Director; HHS Endorses Intramural Scientist Klausner

April 21, 1995

RFA On Role Of Nutrients In Cancer Prevention

June 3, 1983

FDA Orders More Changes In ESA Label,

August 8, 2008

AACI Seeks Change In Cancer Act To Bypass Study Sections On Small Grants With Review By NCAB

March 5, 1982

NCI’s Chabner Cautions Against 3-Hour Taxol Infusion, May Lower Response Rate

October 22, 1993